VanEck Semiconductor ETF vs Zimmer Biomet Holdings Inc — how do they compare? VanEck Semiconductor ETF trades at $603.33 (market cap $73.92B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: VanEck Semiconductor ETF is far larger — about 4.4× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while VanEck Semiconductor ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Semiconductor ETF for 101 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SMH | ZBH | |
|---|---|---|
Market Cap | $73.92B | $16.95B |
Volume | 11,050,892 | 2,505,240 |
52-Week High | $668.91 | $103.98 |
52-Week Low | $325.10 | $79.58 |
Typical Hold Time | 101 Days | 89 Days |
Sector | — | Health |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
SMH (VanEck Semiconductor ETF) trades at $606.82, down 2.91% over the past day amid broader market volatility. The ETF maintains a bullish technical signal with strong moving average support, though oscillators are neutral. Recent news highlights semiconductor sector strength, with SMH up approximately 69% year-to-date in 2026, outperforming many individual stocks like Nvidia. The fund provides diversified exposure to chip leaders, benefiting from AI-driven demand and industry consolidation.
Outlook remains positive given structural growth in AI and semiconductor demand, but risks include high concentration in top holdings, sensitivity to tech sector volatility, and geopolitical trade tensions. Investors should weigh the ETF's historical outperformance against potential reversion risks as valuations stretch.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →